- Atezolizumab, sold
under the
brand name
Tecentriq among others, is a
monoclonal antibody medication used to
treat urothelial carcinoma, non-small cell...
-
deletion and who have been
treated with at
least one
prior therapy. 2016:
Tecentriq (atezolizumab): First-in-class anti-PD-L1
antibody for the
treatment of...
- Atezolizumab/hyaluronidase, sold
under the
brand name
Tecentriq Hybreza, is a fixed-dose
combination medication used for the
treatment of non-small cell...
-
toxicity and myelosuppression. Atezolizumab, sold
under the
brand name
Tecentriq among others, is a
monoclonal antibody medication used to
treat urothelial...
-
Atezolizumab (
Tecentriq), a PD-L1
inhibitor (2018) Tarlatamab, a bi-specific T-cell
engager (2024)
Canadian regulator rejected funding Tecentriq (Atezolizumab)...
- (tolcapone), for parkinson's disease,
licensed by
Mylan and
Bausch Health.
Tecentriq (atezolizumab), for non-small cell lung cancer.
TNKase (tenecteplase)...
-
tecarfarin (USAN)
Tecartus tecastemizole (USAN)
teceleukin (INN)
Tecelra Tecentriq Tecentriq Hybreza Technecoll Technegas Technelite Technescan technetium (99mTc)...
- million. 2016:
Cooperation between Osaka University and
Chugai 2018:
Tecentriq, a
cancer drug, is
launched 2020 – FDA
approved satralizumab (Enspryng)...
- the
United States in
September 2024. Atezolizumab/hyaluronidase-tqjs (
Tecentriq Hybreza) was
approved for
medical use in the
United States in September...
-
switching to
immune checkpoint inhibitors pembrolizumab or
atezolizumab ("
Tecentriq") for long-term
maintenance therapy.
Immune checkpoint inhibitors are...
